Abstract
A key obstacle to the development of new drugs to treat the cognitive deficits of schizophrenia was the absence of a standard by which to measure their efficacy. Before granting approval for any new drug for this condition, the US Food and Drug Administration wanted a standard cognitive endpoint based on a broad consensus-based method. To address this obstacle, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) intiative oversaw a process to develop a consensus neurocognitive battery. Its development included a ten-step process that is described in this article.
| Original language | English |
|---|---|
| Pages (from-to) | 173-186 |
| Number of pages | 14 |
| Journal | Progress in Neurotherapeutics and Neuropsychopharmacology |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2007 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- cognition
- schizophrenia
- tests and measurement
Fingerprint
Dive into the research topics of 'The NIMH matrics initiative: Development of a Consensus Cognitive Battery'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver